Last reviewed · How we verify
Pneumococcal conjugate vaccine GSK 1024850A
Pneumococcal conjugate vaccine GSK 1024850A is a Pneumococcal conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and related infections.
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.
This pneumococcal conjugate vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and related infections.
At a glance
| Generic name | Pneumococcal conjugate vaccine GSK 1024850A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (multiple serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GSK 1024850A is a conjugate vaccine that links pneumococcal capsular polysaccharides from multiple serotypes to a protein carrier, enhancing T-cell dependent immune responses. This approach improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in young children and immunocompromised populations. The vaccine aims to provide broader serotype coverage and more durable protection against invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal pneumonia and related infections
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A (PHASE3)
- Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease (PHASE3)
- Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (PHASE2)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal conjugate vaccine GSK 1024850A CI brief — competitive landscape report
- Pneumococcal conjugate vaccine GSK 1024850A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Pneumococcal conjugate vaccine GSK 1024850A
What is Pneumococcal conjugate vaccine GSK 1024850A?
How does Pneumococcal conjugate vaccine GSK 1024850A work?
What is Pneumococcal conjugate vaccine GSK 1024850A used for?
Who makes Pneumococcal conjugate vaccine GSK 1024850A?
What drug class is Pneumococcal conjugate vaccine GSK 1024850A in?
What development phase is Pneumococcal conjugate vaccine GSK 1024850A in?
What are the side effects of Pneumococcal conjugate vaccine GSK 1024850A?
What does Pneumococcal conjugate vaccine GSK 1024850A target?
Related
- Drug class: All Pneumococcal conjugate vaccine drugs
- Target: All drugs targeting Streptococcus pneumoniae capsular polysaccharides (multiple serotypes)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive pneumococcal disease in infants and children
- Indication: Drugs for Prevention of pneumococcal pneumonia and related infections
- Compare: Pneumococcal conjugate vaccine GSK 1024850A vs similar drugs
- Pricing: Pneumococcal conjugate vaccine GSK 1024850A cost, discount & access